产品名称

Kartogenin - KGN

产品货号

Axon 2378 CAS [4727-31-5] MF C20H15NO3MW 317.34 Purity: 99% Soluble in 0.1N NaOH(aq) and DMSO Description Small molecule promoting robust chondrocyte differentiation from primary human mesenchymal stem cells (MSCs; EC50 value 100 nM). Kartogenin (KGN) treatment of bone marrow stromal cells (BMSCs) induced the expresion of both Col. II and aggrecan in a dose-dependent manner, and upregulates Sox-9 gene expression. KGN does not alter either MMP-3, MMP-13, or aggrecanase expression in primary chondrocytes and MSCs. KGN may be used to enhance tendon/bone interface healing through the direct, local delivery of KGN injections into the gap between the tendon graft and the bone surface during ACL reconstruction. References Certificates Categories Extra info K. Johnson et al. A stem cell-based approach to cartilage repair. Science. 2012, 336, 717-721. J. Zhang et al. Kartogenin induces cartilage-like tissue formation in tendon-bone junction. Bone Res. 2014, 2, pii: 14008. M.L. Kang et al. Intra-articular delivery of kartogenin-conjugated chitosan nano/microparticles for cartilage regeneration. Biomaterials. 2014, 35, 9984-9994. Certificate of Analysis Material Safety Data Sheet Cell Cycle Regulation Pain & Inflammation Stem Cell Stem Cell Differentiator Aggrecan Collagen SOX-9 Promotor of chondrocyte differentiation from primary human MSCs Chemical name 2-(biphenyl-4-ylcarbamoyl)benzoic acid Parent CAS No. [4727-31-5] Order Size Unit Price Stock 10 mg €75.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

Kartogenin - KGN

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2378

CAS [4727-31-5]

MF C20H15NO3
MW 317.34

Purity: 99%
Soluble in 0.1N NaOH(aq) and DMSO

Kartogenin

Description

Small molecule promoting robust chondrocyte differentiation from primary human mesenchymal stem cells (MSCs; EC50 value 100 nM). Kartogenin (KGN) treatment of bone marrow stromal cells (BMSCs) induced the expresion of both Col. II and aggrecan in a dose-dependent manner, and upregulates Sox-9 gene expression. KGN does not alter either MMP-3, MMP-13, or aggrecanase expression in primary chondrocytes and MSCs.
KGN may be used to enhance tendon/bone interface healing through the direct, local delivery of KGN injections into the gap between the tendon graft and the bone surface during ACL reconstruction.